share_log
Moomoo 24/7 ·  04/15 16:15

Oric Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1B Trial of Oric-114 in Patients With Mutated Nsclc

Oric Pharmicals宣布在针对突变非小细胞肺癌患者的Oric-114的1B期试验中,三个扩展队列中首批患者给药

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发